PPIF and myeloid sarcoma: We required a molecule with the following profile: (a) good CypD potency, (b) selectivity for CypD over other cellular cyclophilins by mitochondrial targeting, (c) significant brain levels indicating an ability to target MS lesions, (d) low immunosuppressive activity, and (e) a better cytotoxic profile than CsA.